Alcon Inc.

ALC • Medical - Specialties

$67.50

▼ -0.33 (-0.49%)

Current price

EarningsLatest report: Mar 31, 2026

FAVORABLE PROFILEAttractiveConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Solid company profile with reasonable valuation support. The data suggests a balanced quality/value setup.

Market Cap

$33.16B

Growth

4.7%

Cash Flow

5/5

Trend

Stable

Evidence

Positive revenue growth · 5.6%Positive free cash flow · 3.49Consistent free cash flow · 5/5Manageable debt level · 0.24Healthy liquidity · 2.12

Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 5, 2026, 12:00 AM UTCLast profile update: Aug 12, 2026, 12:35 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$67.50

Change-0.49%

Shares Out490.20M

Market Cap$33.16B

Enterprise Value$36.33B

52W Range61.84 - 90.41

Beta0.70

P/E40.67

P/S3.13

P/B1.49

P/FCF20.32

EV/Sales3.43

Price$67.50

Change-0.49%

Shares Out490.20M

Market Cap$33.16B

Enterprise Value$36.33B

52W Range61.84 - 90.41

Beta0.70

P/E40.67

P/S3.13

P/B1.49

P/FCF20.32

EV/Sales3.43

EV/EBITDA17.10

EV/FCF22.26

Earnings Yield2.46%

FCF Yield4.92%

Dividend Yield0.51%

Gross Margin55.24%

Oper. Margin13.08%

Profit Margin9.42%

Debt/Eq0.24

Current Ratio2.12

Quick Ratio1.33

Revenue 5Y4.65%

FCF 5Y7.45%

Target$72.88

Target Upside7.97%

Target Median$76.50

Target Range35.00 - 85.00

Volume3.69M

Avg Volume2.06M

EPS Surprise0.05

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

69/100

Financial Strength

Debt, cash, stability

74/100

Growth Potential

Revenue and expansion

84/100

Price Attractiveness

Cheap or expensive today

61/100

Why this score▼

Positive revenue growth · 5.6%Positive free cash flow · 3.49Consistent free cash flow · 5/5Manageable debt level · 0.24Healthy liquidity · 2.12Expensive earnings multiple · 39.8

Analyst view

Analyst sentiment and price target

ALC

Analyst sentiment

Based on 26 analyst votes · 2026-10-20

73/100

Bullish

Hold

Bearish

Price Target

2026-08-12

Low

$70.00

Mean

$82.83

Median

$83.50

High

$97.00

Company Overview

IPO: 4/9/2019

Industry: Medical - Specialties

P/B i: 1.49

Debt / Equity i: 0.24

Operating Margin: 13.08%

Net Margin: 9.42%

ROE i: -

ROIC: -

Financial Health

Score15 / 20

Debt / Equity: 0.24

Current Ratio: 2.12

Quick Ratio: 1.33

Status: Good

🧾

No insider activity

No recent insider transactions available.

About the Company

Alcon Inc.

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Source - link

Peers

A BDX CAH GEHC HUM INSM IQV MTD RMD WST

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2

GENEVA--(BUSINESS WIRE)--Alcon Acquires Neurotech and ENCELTO, the Only FDA Approved Treatment for MacTel Type 2.

Business Wire

Algoma Central Corporation Announces $62.5 million Offering of 6.20% Convertible Unsecured Subordinated Debentures

CATHARINES, ONTARIO, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Algoma Central Corporation (“Algoma”) (TSX:ALC) announced today that it has entered into an agreement to sell, on a bought deal basis to a syndicate of underwriters led by CIBC Capital Markets, $50,000,000 aggregate principal amount of 6.20% convertible unsecured subordinated debentures (the “Debentures”) at a price of $1,000 per Debenture (the “Public Offering”).

GlobeNewsWire

FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes

GENEVA--(BUSINESS WIRE)--FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes.

Business Wire

FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes

GENEVA--(BUSINESS WIRE)--FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes.

Business Wire

Credo Expands AI Connectivity Portfolio With 1.6T ZeroFlap ALC

CRDO expands its AI connectivity portfolio with the 1.6T ZeroFlap Active Light Cable, offering lower power consumption, enhanced reliability and extended reach.

Zacks Investment Research

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-05	0.8	0.85	0.05
2026-02-24	0.79	0.78	-0.01
2025-11-11	0.77	0.79	0.02
2025-08-19	0.71	0.76	0.05
2025-05-13	0.76	0.73	-0.03
2025-02-25	0.7	0.72	0.02
2024-11-12	0.72	0.81	0.09
2024-08-20	0.74	0.74	0
2024-05-13	0.72	0.78	0.06
2024-02-27	0.68	0.69	0.01
2023-11-14	0.67	0.66	-0.01
2023-08-15	0.62	0.69	0.07